These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 9603399

  • 1. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
    Foley R, Couban S, Walker I, Greene K, Chen CS, Messner H, Gauldie J.
    Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
    [Abstract] [Full Text] [Related]

  • 2. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M, Ringdén O.
    Transplantation; 1995 Dec 15; 60(11):1293-9. PubMed ID: 8525524
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May 15; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 6. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
    Grimm J, Zeller W, Zander AR.
    Bone Marrow Transplant; 1998 Jan 15; 21(1):29-32. PubMed ID: 9486491
    [Abstract] [Full Text] [Related]

  • 7. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
    Mehta R, Shah G, Adler W, Kittur D.
    Clin Transplant; 2004 Jan 15; 18 Suppl 12():67-71. PubMed ID: 15217411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
    Engelhard D, Nagler A, Singer R, Barak V.
    Leuk Lymphoma; 1994 Jan 15; 12(3-4):273-80. PubMed ID: 8167558
    [Abstract] [Full Text] [Related]

  • 10. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J, Casaño J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F, Gomez P, Serrano J, Herrera C, Torres A.
    Br J Haematol; 2004 Sep 15; 126(5):697-703. PubMed ID: 15327522
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C, Stephan JL, Donadieu J, Le Deist F, Racadot E, Wijdenes J, Fischer A.
    Bone Marrow Transplant; 1994 May 15; 13(5):563-9. PubMed ID: 8054909
    [Abstract] [Full Text] [Related]

  • 13. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
    Moon Y, Kim Y, Kim M, Lim J, Kang CS, Kim WI, Shim SI, Chung NG, Park YH, Min WS, Han K.
    Ann Clin Lab Sci; 2004 May 15; 34(4):410-5. PubMed ID: 15648782
    [Abstract] [Full Text] [Related]

  • 14. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
    Ferrà C, de Sanjosé S, Gallardo D, Berlanga JJ, Rueda F, Marìn D, de la Banda E, Ancìn I, Peris J, Garcìa J, Grañena A.
    Haematologica; 1998 Dec 15; 83(12):1082-7. PubMed ID: 9949625
    [Abstract] [Full Text] [Related]

  • 15. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep 15; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 16. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.
    Imoto S, Oomoto Y, Murata K, Das H, Murayama T, Kajimoto K, Sugimoto T, Gomyo H, Nakagawa T, Nishimura R, Koizumi T.
    Int J Hematol; 2000 Jul 15; 72(1):92-7. PubMed ID: 10979216
    [Abstract] [Full Text] [Related]

  • 17. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, Saunders EF, Calderwood S, Doyle JJ.
    Br J Haematol; 2002 Feb 15; 116(2):483-90. PubMed ID: 11841456
    [Abstract] [Full Text] [Related]

  • 18. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
    MacMillan ML, Radloff GA, Kiffmeyer WR, DeFor TE, Weisdorf DJ, Davies SM.
    Transplantation; 2003 Dec 27; 76(12):1758-62. PubMed ID: 14688528
    [Abstract] [Full Text] [Related]

  • 19. Soluble interleukin 2 receptors in patients after bone marrow transplantation.
    Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA, Musch R, Schmid HJ, Hartmann R, Henze G, Huhn D.
    Bone Marrow Transplant; 1990 Aug 27; 6(2):97-101. PubMed ID: 2207458
    [Abstract] [Full Text] [Related]

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 27; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.